This is a Mint Premium article gifted to you.Subscribe to enjoy similar stories.
With its $11.75 billion acquisition of Organon, a Merck spinoff, Sun Pharmaceutical has officially embarked on one of the most ambitious overseas expansions ever by an Indian pharmaceutical company. Markets cheered the announcement on 27 April, sending the stock soaring almost 8%.
This reflects optimism around scale expansion and strategic repositioning. With Organon’s $6.2 billion revenue and $1.9 billion Ebitda in CY25, the combined entity will hit a revenue of $12.4 billion, basis FY25 revenues for Sun Pharma. Ebitda stands for earnings before interest, taxes, depreciation, and amortization.
For a company long seen primarily as a specialty generics exporter, this acquisition strengthens its pivot toward global branded and specialty therapies.
Organon brings three structural advantages – leadership in women’s health – an underpenetrated segment with strong pricing power; a robust biosimilars platform – exactly what the doctor ordered for pharma companies seeking higher-margin growth amid frequent pricing pressures in the competitive generics market; and geographic diversification across 18 large markets generating over $100 million each. The complementary footprint creates presence in all key regions, expanding Europe and adding China and Korea.
The combined entity will become one of the top-3 global women’s health players, rank among the top-7 biosimilars companies, and lift the share of innovative medicines from 20% to 27%.
But the risks – leverage, valuation, and execution – are worth noting.
The transaction will be partly funded by bank financing to cover almost $8 billion of net debt on Organon’s books. This will flip Sun Pharma from a net-cash position to roughly 2.3x net-debt-to-Ebitda. While Organon’s debt is at lower rates, and the management expects cash flows to eventually double, enabling gradual deleveraging back into a net cash position within the next three-four years, the immediate shift in debt profile is meaningful.
“Valuation for the deal works out to be 6.2x trailing EV/Ebitda, which is reasonable,” as per Elara Securities. Organon’s share price had fallen sharply from nearly $40 in 2022 to below $6 by March 2026, thanks to struggling growth with stagnant revenues over several years, and governance concerns, including sales irregularities and leadership changes.
The acquisition is margin and EPS-accretive from the first year, although growth for the combined entity may fall to mid-single digits, compared to 10-12% for Sun Pharma alone, said Mehul Sheth, analyst at HDFC Securities. So, Sun Pharma may be overpaying at $14 a share, a 24% premium over already-rebounding levels.
Cross-border integration remains the final variable, with regulatory systems and commercial structure alignment expected to push closure to 2027. If integration falters, balance sheet could become the story.
Ananya Roy is the Founder of Credibull Capital, a SEBI-registered investment adviser, where she focuses on building disciplined, research-driven investment strategies for long-term wealth creation. A CFA charterholder with an MBA in Finance from a premier IIM and an engineering degree from NIT, she combines strong academic grounding with nearly 15 years of hands-on experience across the investment management spectrum.Her career spans index construction, portfolio management, and private equity investing, giving her a 360-degree perspective on capital markets. Prior to founding Credibull Capital, she held key roles at Edelweiss, Reliance PMS, and Morningstar, where she was involved in fund management, equity research, and product development. This diverse exposure enables her to seamlessly connect macroeconomic trends with bottom-up stock selection.Ananya is known for her ability to simplify complex financial concepts and translate them into actionable insights for investors. She writes extensively on the economy, market trends, regulatory developments, and personal finance, with her work also featured in leading publications such as Moneycontrol, The Economic Times, and Financial Express.Deeply passionate about investing, she enjoys immersing herself in detailed industry analysis and company fundamentals, constantly seeking to uncover high-conviction opportunities. Her investment philosophy is rooted in patience, discipline, and a sharp focus on risk-adjusted returns.